Startseite

AI-driven analysis of atrial fibrillation burden in pacemaker patients reveals no effect of AF burden on stroke

by

An analysis of the NOAH – AFNET 6 trial used large language models to extract AF burden from pacemaker data in patients with device-detected atrial fibrillation. This approach enables to evaluate the impact of AF burden on cardiovascular outcome and on the effectiveness and safety of anticoagulation in pacemaker patients. The AF burden in the population was 0.4%, with 20% of patients showing a baseline AF burden of more than 1%. In these patients, there was no effect of AF burden on stroke or other cardiovascular events. Today, the findings were presented by AFNET board member Prof. Ulrich Schotten, Maastricht, as a hotline at the Heart Rhythm congress 2026 in Chicago (1).

3rd AFNET DGK Young Investigator Award – Atrial Fibrillation 2026

by

Once again, four young scientists were honored with the AFNET-sponsored “DGK AFNET Young Investigator Award” for their current research on atrial fibrillation. AFNET Board Member and this year’s DGK Conference President Prof. Dr. Stephan Willems congratulated the award recipients during the award ceremony on April 10, 2026 at the DGK Annual Congress.

3rd AFNET Lecture Award 2026

by

As part of the “23 Years of AFNET” session, Prof. Steinbeck presented the AFNET Lecture titled “EP Studies Revisited.” For his long-standing commitment, he received this year’s DGK-AFNET Lecture Award, which was presented for the third time. Prof. Sinner presented the results of the 10th AFNET-EHRA Consensus Conference.

Kidney disease increases the risk of cardiovascular events in patients with device-detected atrial fibrillation

by

A prespecified analysis of the NOAH – AFNET 6 trial investigated the impact of kidney function on cardiovascular outcome in patients with device-detected atrial fibrillation. Today, the findings were presented by AFNET board member Prof. Andreas Goette, St. Vincenz Hospital, Paderborn, Germany, at the annual congress of the European Heart Rhythm Association (EHRA) in Paris and published in the EP Europace journal (1,2).

AF-B STEP: Global collaboration to reduce the burden of atrial fibrillation and advance quantification and treatment

by

Atrial fibrillation (AF) affects millions of people worldwide – yet the condition is rarely quantified upon diagnosis. The international research project AF-B-STEP aims to change this: for the first time, it will systematically assess how much time individuals spend in AF, expressed as their AF burden, and determine the extent to which the AF burden influences the risk of stroke, heart failure and other aspects of patients´ lives.

Transforming Atrial Fibrillation Management by Targeting Comorbidities and Reducing Atrial Fibrillation Burden – an AFNET/EHRA position paper

by

Patient:innen mit einem akuten Schlaganfall und gleichzeitig bestehendem Vorhofflimmern haben ein besonders hohes Risiko für einen erneuten Schlaganfall und andere schwerwiegende kardiovaskuläre Ereignisse. In einer europaweiten klinischen Studie unter Leitung von Wissenschaftler:innen des Universitätsklinikums Hamburg-Eppendorf (UKE) wird jetzt  geprüft, ob eine frühe rhythmuserhaltende Behandlung Schlaganfälle effektiv und sicher verhindern kann.  Die EU fördert das Projekt in den kommenden sechs Jahren mit sieben Millionen Euro.